A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

• ClinicalTrials.gov Identifier: NCT05548296
• Recruitment Status: Recruiting
• First Posted: September 21, 2022
• Last Update Posted: April 2, 2024
• Sponsor: Acrivon Therapeutics
• Collaborator: GOG Foundation
• Information provided by (Responsible Party): Acrivon Therapeutics

Tracking Information

• First Submitted Date: August 29, 2022
• First Posted Date: September 21, 2022
• Last Update Posted Date: April 2, 2024
• Actual Study Start Date: August 29, 2022
• Estimated Primary Completion Date: July 31, 2026 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: June 20, 2023)

• Arm 1 Monotherapy: Anti-tumor activity of ACR-368 in Ovarian, Endometrial, and Urothelial Cohorts [ Time Frame: Response will be assessed every 8 weeks from baseline through 2 years or death. ]
  Assess Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging for the number of participants with a partial or complete response.
• Arm 2 Phase 1b: Adverse Events (AEs) for ACR-368 in combination with ULDG [ Time Frame: AEs will be assessed from baseline through 2 years or death. ]
  Safety will be assessed by the incidence of AEs characterized overall and by type, incidence, severity graded according to NCI CTCAE v5.0, seriousness, and relationship to study treatment.
• Arm 2 Phase 1b: Determine the RP2D of ULDG [ Time Frame: AEs will be assessed from first dose of ULDG for 28 days for each subject in a cohort. ]
  The RP2D will be evaluated by the incidence of DLT events per dose level
• Arm 2 Exploratory Phase 2: Anti-tumor activity of ACR-368 plus ULDG in Ovarian, Endometrial and Urothelial Cohorts [ Time Frame: Response will be assessed every 8 weeks from baseline through 2 years or death. ]
  Assess Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging for the number of participants with a partial or complete response.

Original Primary Outcome Measures (submitted: September 16, 2022)

• Arm 1 Monotherapy: Anti-tumor activity of ACR-368 in Ovarian, Endometrial, and Urothelial Cohorts [ Time Frame: Response will be assessed every 8 weeks from baseline through 2 years or death. ]
  Assess Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging for the number of participants with a partial or complete response.
• Arm 2 Phase 1b: Adverse Events (AEs) for ACR-368 in combination with LDG [ Time Frame: AEs will be assessed from baseline through 2 years or death. ]
  Safety will be assessed by the incidence of AEs characterized overall and by type, incidence, severity graded according to NCI CTCAE v5.0, seriousness, and relationship to study treatment.
• Arm 2 Phase 1b: Determine the RP2D of LDG [ Time Frame: AEs will be assessed from first dose of LDG for 28 days for each subject in a cohort. ]
  The RP2D will be evaluated by the incidence of DLT events per dose level
• Arm 2 Exploratory Phase 2: Anti-tumor activity of ACR-368 plus LDG in Ovarian, Endometrial and Urothelial Cohorts [ Time Frame: Response will be assessed every 8 weeks from baseline through 2 years or death. ]
  Assess Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging for the number of participants with a partial or complete response.

Current Secondary Outcome Measures (submitted: June 20, 2023)

• Arm 1: Number of subjects with confirmed OncoSignature thresholds for enrichment of ACR-368 monotherapy responders [ Time Frame: Baseline to first post treatment imaging at 8 weeks ]
  Response data including tumor shrinkage at first imaging and progression by computed tomography or magnetic resonance imaging for the first 12 participants in each tumor type
• Arm 1: Adverse Events (AEs) for ACR-368 monotherapy [ Time Frame: AEs will be assessed from baseline through 2 years or death. ]
  Safety will be assessed by the incidence of AEs characterized overall and by type, incidence, severity graded according to NCI CTCAE v5.0, seriousness, and relationship to study treatment.
• Relative dose intensity of ACR-368 [ Time Frame: First dose of ACR-368 in first cycle to dose on day 15 of second cycle of administration ]
  Assess the ratio of cumulative administered dose to the planned dose for first 2 cycles
• Arm 1: Limited pharmacokinetic (PK) testing in participants with Ovarian Carcinoma [ Time Frame: Dose of ACR-368 at day 1 and day 15 of first cycle ]
  Cmax will be assessed in the first cycle at baseline, end of infusion, hour 2 and hour 4
• Arm 2: Limited pharmacokinetic (PK) testing of ACR-368 in combination with ULDG in all participants in Phase 1b [ Time Frame: Dose of ACR-368 at day 1 and day 15 of first cycle ]
  Cmax will be assessed in the first cycle at baseline, end of infusion, hour 2 and hour 4
• Overall Survival (OS) [ Time Frame: Up to 2 years ]
  The time from baseline until date of death
• Duration of Response (DOR) [ Time Frame: Up to 2 years ]
  The time from initial response until investigator assessed progressive disease for all subjects who achieve a confirmed objective response.
• Progression-free Survival (PFS) [ Time Frame: Up to 2 years ]
  The time from baseline until second disease progression or death whichever occurs first.

Original Secondary Outcome Measures (submitted: September 16, 2022)

• Arm 1: Number of subjects with confirmed OncoSignature thresholds for enrichment of ACR-368 monotherapy responders [ Time Frame: Baseline to first post treatment imaging at 8 weeks ]
  Response data including tumor shrinkage at first imaging and progression by computed tomography or magnetic resonance imaging for the first 12 participants in each tumor type
• Arm 1: Adverse Events (AEs) for ACR-368 monotherapy [ Time Frame: AEs will be assessed from baseline through 2 years or death. ]
  Safety will be assessed by the incidence of AEs characterized overall and by type, incidence, severity graded according to NCI CTCAE v5.0, seriousness, and relationship to study treatment.
• Relative dose intensity of ACR-368 [ Time Frame: First dose of ACR-368 in first cycle to dose on day 15 of second cycle of administration ]
  Assess the ratio of cumulative administered dose to the planned dose for first 2 cycles
• Arm 1: Limited pharmacokinetic (PK) testing in participants with Ovarian Carcinoma [ Time Frame: Dose of ACR-368 at day 1 and day 15 of first cycle ]
  Cmax will be assessed in the first cycle at baseline, end of infusion, hour 2 and hour 4
• Arm 2: Limited pharmacokinetic (PK) testing of ACR-368 in combination with LDG in all participants in Phase 1b [ Time Frame: Dose of ACR-368 at day 1 and day 15 of first cycle ]
  Cmax will be assessed in the first cycle at baseline, end of infusion, hour 2 and hour 4
• Overall Survival (OS) [ Time Frame: Up to 2 years ]
  The time from baseline until date of death
• Duration of Response (DOR) [ Time Frame: Up to 2 years ]
  The time from initial response until investigator assessed progressive disease for all subjects who achieve a confirmed objective response.
• Progression-free Survival (PFS) [ Time Frame: Up to 2 years ]
  The time from baseline until second disease progression or death whichever occurs first.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
• Official Title: A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination With Gemcitabine in Adult Subjects With Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
• Brief Summary: This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignature® test status.

Detailed Description

Participants will be selected for predicted efficacy of ACR-368 using the OncoSignature® Companion Diagnostic test. Participants will be allocated to one of 2 arms based on OncoSignature result:

Arm 1: OncoSignature Positive tumors

Arm 2: OncoSignature Negative

Participants in Arm 1 will receive ACR-368 as monotherapy. Participants in Arm 2 will receive the combination of ACR-368 and ultralow-dose gemcitabine. Participants in both arms will be treated until disease progression, unacceptable toxicity or any criterion for stopping the study drug or withdrawal from the trial occurs.

• Study Type: Interventional
• Study Phase: Phase 1; Phase 2

Study Design

Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Participants with an OncoSignature positive test will enter a Phase 2 study that will assess the efficacy of ACR-368 as monotherapy in each of the 3 tumor types, ovarian, endometrial, and urothelial carcinomas. Participants with an OncoSignature negative test will be entered in a Phase 1b study to assess the safety of the combination of ACR-368 and escalating doses of ultralow dose gemcitabine (ULDG) in each of the 3 tumor types. When the recommended Phase 2 (RP2D) dose is determined, participants will be entered in an exploratory Phase 2 study to assess the efficacy and safety of ACR-368 and the RP2D of ULDG in each of the 3 tumor types.

Masking: None (Open Label)
Primary Purpose: Treatment

Condition

• Platinum-resistant Ovarian Cancer
• Endometrial Adenocarcinoma
• Urothelial Carcinoma

Intervention

• Drug: ACR-368
  ACR-368 is an experimental drug
  Other Name: prexasertib
• Drug: Gemcitabine
  Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368
• Diagnostic Test: OncoSignature
  Biomarker profile based on prediction of drug sensitivity performed on biopsy tissue

Study Arms

• Experimental: OncoSignature Positive Tumors
  In Arm 1, participants with an OncoSignature Positive test will enter a Phase 2 Simon 2-Stage Study that will assess the efficacy of ACR-368 as monotherapy in each of the 3 cohorts of participants (ovarian, endometrial, and urothelial).
  Interventions:

  • Drug: ACR-368
  • Diagnostic Test: OncoSignature
• Experimental: OncoSignature Negative or Unevaluable test
  In Arm 2, participants with an OncoSignature Negative will receive the combination of ACR-368 and ultralow Dose Gemcitabine (ULDG). The Phase 1b/2 portion will only enroll participants with OncoSignature Negative tumors. Unevaluable tumors will not be able to participate. A Phase 1b Study will assess the safety of the combination of ACR-368 and escalating doses of ULDG in participants with any of the 3 tumor types (ovarian, endometrial, and urothelial). The Phase 1b Study will determine the recommended Phase 2 dose (RP2D) of ULDG. When determined, a Phase 2 Exploratory Study will be initiated to assess the efficacy and safety of the combination of ACR-368 and the RP2D of ULDG in each of the 3 cohorts of participants (ovarian, endometrial, and urothelial).
  Interventions:

  • Drug: ACR-368
  • Drug: Gemcitabine
  • Diagnostic Test: OncoSignature

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: June 20, 2023): 390
• Original Estimated Enrollment (submitted: September 16, 2022): 333
• Estimated Study Completion Date: December 31, 2027
• Estimated Primary Completion Date: July 31, 2026 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criterial: General

1. Participant must be able to give signed, written informed consent.
2. Participant must have histologically confirmed, locally advanced (i.e., not amenable to curative surgery and/or radiation therapy) or metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen.

3. Participant must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria (by local Investigator) (Eisenhauer, 2009).

   Participant must have radiographic evidence of disease progression based on RECIST criteria following the most recent line of treatment. Biochemical recurrence (eg, CA-125 in ovarian carcinoma) only is not considered as disease progression.

4. Participant must be willing to provide tissue from a newly obtained tumor biopsy from an accessible tumor lesion not previously irradiated after signed informed consent.

   Newly obtained is defined as a specimen obtained up to 6 weeks prior to initiation of treatment on Day 1 if no intercurrent systemic therapy in the interval.

5. Participant must be willing to provide an archival tumor tissue block or at least 20 unstained slides, if available.

6. Participant must have stabilized or recovered (Grade 1 or baseline) from all prior therapy related toxicities, except as follows:

   • Alopecia is accepted.
   • Endocrine events from prior immunotherapy stabilized at ≤ Grade 2 due to need for replacement therapy are accepted (including hypothyroidism, diabetes mellitus, or adrenal insufficiency).
   • Neuropathy events from prior cytotoxic therapies stabilized at ≤ Grade 2 are accepted.
7. Participant must have an Eastern Cooperative Oncology Group Performance Status 0 or 1.
8. Participant must have an estimated life expectancy of longer than 3 months.

9. Participant must have adequate organ function at Screening, defined as:

   • Absolute neutrophil count > 1500 cells/µL without growth factor support within 1 week prior to obtaining the hematology values at Screening.
   • Hemoglobin ≥ 9.0 g/dL without transfusion or growth factor support within 2 weeks prior to obtaining the hematology values at Screening.
   • Platelets ≥ 100,000 cells/µL without transfusion within 1 week prior to obtaining the hematology values at Screening.
   • Calculated creatinine clearance ≥ 30 mL/min as calculated by the Cockcroft Gault formula.
   • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); ≤ 5 × ULN if liver metastases are present.
   • Total bilirubin ≤ 1.5 × ULN not associated with Gilbert's syndrome. If associated with Gilbert's syndrome ≤ 3 x ULN is acceptable.
   • Serum albumin ≥ 3 g/dL.
10. Participant must have adequate coagulation profile as defined below (including if receiving anticoagulation therapy): Prothrombin time within 1.5 x ULN. Activated partial thromboplastin time within 1.5 x ULN. If the patient is anticoagulated, must be on a stable dose of anticoagulant for ≥ 1 month.

Tumor Specific Inclusion Criteria

For Ovarian Carcinoma:

1. Participant must have histologically documented, platinum resistant, advanced (metastatic and/or unresectable) high-grade serous/endometrioid ovarian, primary peritoneal, or fallopian tube cancer. Platinum-resistant disease, defined as progression or relapse within 6 months after the completion of platinum-based therapy, is eligible.

   Platinum sensitive disease, defined as disease which progress after 6 or more months after the completion of platinum-based therapy and primary platinum refractory disease, defined as progression while on the upfront platinum-based therapy, is not eligible.

   a. Carcinosarcoma is eligible.

2. Participant must have received at least 1 but no more than 6 prior lines of systemic therapy, including at least 1 line of therapy containing platinum derivative and taxane, and single-agent therapy must be appropriate as the next line of treatment:
3. Participant must have had prior bevacizumab or did not receive bevacizumab based on Investigator judgment (see Section 2.1.1).

For Endometrial Carcinoma

1. Participant must have histologically documented, high-grade endometrial adenocarcinoma.

   1. All Grade 3 International Federation of Gynecology and Obstetrics epithelial endometrial histologies are eligible including: endometrioid, serous, and clear-cell carcinoma.
   2. Carcinosarcoma is eligible. Enrollment of participants with this histology will be capped at 5% for each cohort.
   3. Participant must have no more than 3 prior lines of therapy in the recurrent setting, including platinum-based chemotherapy for subtypes of endometrial adenocarcinoma where it is a standard of care.
2. Participant must have documented failure or ineligibility (based on Investigator judgement) for prior anti-programmed cell death protein 1/anti-programmed death- ligand 1 (PD 1/PD L1) based therapy for advanced/metastatic disease. Prior combination of PD 1/PD L1 inhibitor and vascular endothelial growth factor tyrosine kinase inhibitor is acceptable.

For Urothelial Carcinoma

1. Participant must have histologically documented, advanced (metastatic and/or unresectable) urothelial carcinoma. Variant histology is allowed as long as the tumor is predominantly urothelial.

2. Participants must have:

   1. Received a platinum containing regimen (cisplatin or carboplatin) in the metastatic/locally advanced, neoadjuvant, or adjuvant setting. If platinum was administered in the adjuvant/neoadjuvant setting, participant must have progressed within 12 months of completion.
   2. Failed or have been ineligible for checkpoint inhibitors (including PD-1 or PD-L1 inhibitors).
   3. Failed or have been ineligible for enfortumab vedotin.
   4. Have no known life-prolonging therapy available

Exclusion Criteria: General

1. Participant with known symptomatic brain metastases requiring > 10 mg/day of prednisolone (or its equivalent). Participants with previously diagnosed brain metastases are eligible if they have completed their treatment, have recovered from the acute effects of radiation therapy or surgery prior to the start of ACR-368 treatment, fulfill the steroid requirement for these metastases, and are neurologically stable based on central nervous system imaging ≥ 4 weeks after treatment.

2. Participant had a failure to recover from the reversible effects of prior anti-cancer therapy, as follows:

   1. Endocrine events from prior immunotherapy at Grade > 2.
   2. Neuropathy events from prior cytotoxic therapies at Grade > 2.
   3. All other reversible effects of prior anti- cancer therapy (except alopecia) at Grade >1 or Baseline.
3. Participant had systemic therapy or radiation therapy within 2 weeks prior to the first dose of study drug.
4. Participants has known human immunodeficiency virus, hepatitis B, or hepatitis C infection that is considered uncontrolled based on the criteria included in Appendix 2.
5. Participant has a history of clinically meaningful coagulopathy, bleeding diathesis.

6. Participant has cardiovascular disease, defined as:

   1. Uncontrolled hypertension defined as blood pressure > 160/90 mmHg at Screening confirmed by repeat (medication permitted).
   2. History of torsades de pointes, significant Screening electrocardiogram (ECG) abnormalities, including ventricular rhythm disturbances, unstable cardiac arrhythmia requiring medication, pathologic symptomatic bradycardia, left bundle branch block, second degree atrioventricular (AV) block type II, third degree AV block, Grade ≥ 2 bradycardia, uncorrected hypokalemia not amenable to correction, congenital long QT syndrome, prolonged QT interval due to medications, corrected QT (QTc) > 450 msec (for men) or > 470 msec (for women).
   3. Symptomatic heart failure (per New York Heart Association guidelines; (Caraballo, 2019), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction < 20%, transient ischemic attack, or cerebrovascular accident within 6 months of Day 1).
7. Participant has a history of major surgery within 4 weeks of Screening.
8. Participant has a history of bowel obstruction requiring decompression through a nasogastric tube within 8 weeks of Screening. Participants has signs or symptoms of intestinal obstruction, which include nausea, vomiting, and objective radiologic finding of bowel obstruction.
9. Participant has taken a prior cell cycle CHK1 inhibitor, including ACR-368

Tumor Specific Exclusion Criteria

For Ovarian Carcinoma:

1. Participant has non-epithelial carcinoma, clear-cell, mucinous, germ-cell, low-grade serous, or low-grade endometrioid carcinoma.
2. Participant has a history of clinically meaningful ascites, defined as a history of paracentesis or thoracentesis within 4 weeks of Screening. Participant has a planned therapeutic paracentesis or thoracentesis between Screening and Cycle 1 Day 1 dosing.
3. Participant has a history of active inflammatory bowel disease within 2 years prior to Screening.
4. Participant has a history of bowel perforation, fistula, necrosis, or leak within 8 weeks of Screening.

For Endometrial Adenocarcinoma:

1. Participant has low-grade endometrioid carcinoma.
2. Participant has mesenchymal tumors of the uterus.
3. Participant has a history of clinically meaningful ascites, defined as a history of paracentesis or thoracentesis within 4 weeks of Screening. Participant has a planned therapeutic paracentesis or thoracentesis between Screening and Cycle 1 Day 1 dosing.

For Urothelial Carcinoma:

1. Participant has sarcoma, carcinosarcoma, melanoma, or lymphoma of the bladder.
2. Participant has not received a previous platinum-based regimen.
3. Participant has small cell or neuroendocrine histology.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Jean-Marie Cuillerot, MD; 617-207-8976; ACR-368-201ClinicalTrial@acrivon.com

Contact: Jeanie Tang; ACR-368-201ClinicalTrial@acrivon.com

• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT05548296
• Other Study ID Numbers: ACR-368-201 (GOG 3082)
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: Yes
• Device Product Not Approved or Cleared by U.S. FDA: Yes

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Acrivon Therapeutics
• Original Responsible Party: Same as current
• Current Study Sponsor: Acrivon Therapeutics
• Original Study Sponsor: Same as current
• Collaborators: GOG Foundation

Investigators

• Principal Investigator: Jung-Min Lee, MD; National Cancer Institute (NCI)
• Principal Investigator: Jonathan Rosenberg, MD; Memorial Sloan-Kettering Cancer Center (MSKCC)

• PRS Account: Acrivon Therapeutics
• Verification Date: April 2024